[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-353802-105":3,"doc-detail-353802-en":81,"detail-sidebar-cat-0-en-105":116},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","identification-of-a-tertiary-lymphoid-structure-signature-for-predicting-tumor-outcomes-through-transcriptomics-analysis-research","Identification of a Tertiary Lymphoid Structure Signature for Predicting Tumor Outcomes Through Transcriptomics Analysis - Research","","Tertiary lymphoid structures (TLSs) regulate tumor invasion and metastasis and can act as prognostic biomarkers for immunotherapy, yet available TLS assessments depend on limited gene signatures and lack broad, pan-cancer feature sets. This study systematically evaluates six published TLS gene signatures against immune-related indicators using TCGA tumor datasets and multiple immune checkpoint blockade cohorts, then builds a de novo TLS-related feature set, predictTLS, via meta-analysis. Internal validation, single-cell RNA-seq, and spatial transcriptomics confirm its predictive value for ICB efficacy and patient prognosis across cancers.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/identification-of-a-tertiary-lymphoid-structure-signature-for-predicting-tumor-outcomes-through-transcriptomics-analysis-research/353802/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/identification-of-a-tertiary-lymphoid-structure-signature-for-predicting-tumor-outcomes-through-transcriptomics-analysis-research/353802.png","ImageObject",300,407,{"name":42,"@type":43},"River Wang","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main goal of this study?","Question",{"text":63,"@type":64},"To develop and validate a de novo TLS-related gene signature (predictTLS) that predicts immune checkpoint blockade efficacy and tumor prognosis across multiple cancer types.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were existing and newly constructed TLS signatures evaluated?",{"text":68,"@type":64},"Six published TLS gene signatures were systematically assessed using TCGA data and immune checkpoint blockade cohorts, followed by constructing predictTLS through meta-analysis.",{"name":70,"@type":61,"acceptedAnswer":71},"What evidence supports the robustness of predictTLS?",{"text":72,"@type":64},"Validation across internal datasets, single-cell transcriptomic data, and spatial transcriptomic data supports both effectiveness and biological relevance.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},353802,1790531507,{"code":4,"msg":82,"data":83},"success",{"doc_id":79,"user_id":84,"nickname":42,"user_avatar":85,"doc_module":4,"category_id":86,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":87,"file_id":88,"file_url":89,"file_type":90,"file_size":91,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":92,"language":93,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":94,"faqs":95,"seo_title":96,"seo_description":12,"update_tm":97,"read_time":98,"preview_page_count":33,"preview_urls":99},1099514067438,"https://ap-avatar.wpscdn.com/avatar/100002539ee87300030?x-image-process=image/resize,m_fixed,w_180,h_180&k=1780474512215547542",8,"Article  \nIdentification of a Tertiary Lymphoid Structure Signature for Predicting Tumor Outcomes Through Transcriptomics Analysis  \nMengdi Zhou 1,2,†, Fangliangzi Meng 3,†, Fan Wu 1,* and Chi Zhou 1, *  \nAcademic Editors: Ilya Ioshikhes and Albert Jeltsch  \nReceived: 27 January 2026  \nRevised: 12 February 2026  \nAccepted: 13 February 2026  \nPublished: 16 February 2026  \nCopyright: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \n1 Shanghai Immune Therapy Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China; [mdzhou@innostarbio.com](mdzhou@innostarbio.com)  \n2 Shanghai InnoStar Bio-Tech Co., Ltd., Shanghai 200092, China  \n3 Bioinformatics Department, School of Life Sciences and Technology, Tongji University, Shanghai 200092, China; [1911007@tongji.edu.cn](1911007@tongji.edu.cn)  \n* [Correspondence: wufan@renji.com](Correspondence: wufan@renji.com) (F.W.); [zhouchi_renji@sjtu.edu.cn](zhouchi_renji@sjtu.edu.cn) (C.Z.)† These authors contributed equally to this work.  \nAbstract  \nBackground: Tertiary lymphoid structures (TLSs) play a crucial role in regulating tumor invasion and metastasis and serve as a promising prognostic biomarker in immunotherapy, influencing survival and immune response in multiple cancers. However, existing studies rely on limited gene signatures to assess TLSs, and there remains a lack of comprehensive TLS-related features for pan-cancer prognosis or immunotherapy response prediction. Methods: Based on published TLS gene signatures, mutation data, and expression profiles from 33 tumor types in TCGA, along with data from 15 immune checkpoint blockade (ICB) cohorts, we first systematically evaluated six TLS gene signatures in relation to immune-related indicators and assessed their predictive and prognostic performance across tumors and immunotherapy. Subsequently, using meta-analysis, we constructed a de novo TLS-related gene feature set, termed predictTLS, designed to predict ICB efficacy and prognosis. The rationality and effectiveness of predictTLS were validated using internal validation sets, single-cell transcriptomic, and spatial transcriptomic data. Results: The evaluation revealed associations between TLS gene signatures and key immune-related indicators. The newly constructed predictTLS feature set demonstrated effectiveness in predicting both ICB therapy outcomes and patient prognosis across the analyzed cohorts. Validation across internal datasets, single-cell profiles, and spatial transcriptomics supported the robustness and biological relevance of predictTLS. Conclusions: This study provides a systematically validated, de novo TLS-related gene signature that can serve as a clinical biomarker for predicting immunotherapy response and prognosis in pan-cancer settings. These findings offer new tools for risk stratification and potential therapeutic targeting in tumor immunotherapy.  \nKeywords: cancer genomics; tertiary lymphoid structures; meta-analysis; tumor prognosis; single-cell sequencing; spatial transcriptome  \n1. Introduction  \nAs cancer progresses, tumor cells experience genomic, epigenetic, and morphological alterations within particular tissues before they start metastasizing to other organs [1–3] . Accumulated genetic mutations in tumor cells result in the expression of tumor antigens, which activate both innate and adaptive immune responses to target and eliminate the cancer cells [4,5] . Typically, effective adaptive immune responses against cancer occur in  \nsecondary lymphoid organs (SLO) [6] . However, further research on the tumor microenvironment (TME) has revealed the mechanisms underlying the generation and regulation of anti-tumor immune responses. Studies have shown that anti-tumor immune responses occur not only in SLO but also directly within organized cellular aggregates at the tu","cbCaieg48H9WTR38","https://ap.wps.com/l/cbCaieg48H9WTR38","pdf",24643346,19,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Introduction","[{\"question\":\"What is the main goal of this study?\",\"answer\":\"To develop and validate a de novo TLS-related gene signature (predictTLS) that predicts immune checkpoint blockade efficacy and tumor prognosis across multiple cancer types.\"},{\"question\":\"How were existing and newly constructed TLS signatures evaluated?\",\"answer\":\"Six published TLS gene signatures were systematically assessed using TCGA data and immune checkpoint blockade cohorts, followed by constructing predictTLS through meta-analysis.\"},{\"question\":\"What evidence supports the robustness of predictTLS?\",\"answer\":\"Validation across internal datasets, single-cell transcriptomic data, and spatial transcriptomic data supports both effectiveness and biological relevance.\"}]","Identification of a Tertiary Lymphoid Structure Signature for Predicting Tumor Outcomes Through Transcriptomics Analysis - Research | PDF",1790107319,48,[100,104,108,112],{"page_no":22,"url":101,"width":102,"height":103},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7275685128aac14af6382b86dde6316c.webp",983,1390,{"page_no":26,"url":105,"width":106,"height":107},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d6d87bc941d57d48eb9185307c481147.webp",982,1388,{"page_no":30,"url":109,"width":110,"height":111},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6542e8f5e55df4843a8e59376d31c9f4.webp",981,1387,{"page_no":33,"url":113,"width":114,"height":115},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7b10b083a9f617b9407eb19411d04cde.webp",980,1385,{"code":4,"msg":82,"data":117},[118,122,126,130,135,140,145,148,153,156,159],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":119,"show_sort_weight":120,"slug":121},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":123,"show_sort_weight":124,"slug":125},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":127,"show_sort_weight":128,"slug":129},"Exam",70,"exam",{"id":131,"doc_module":4,"doc_module_name":25,"category_name":132,"show_sort_weight":133,"slug":134},5,"Comic",60,"comic",{"id":136,"doc_module":4,"doc_module_name":25,"category_name":137,"show_sort_weight":138,"slug":139},6,"Technology",50,"technology",{"id":141,"doc_module":4,"doc_module_name":25,"category_name":142,"show_sort_weight":143,"slug":144},7,"Healthcare",40,"healthcare",{"id":86,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":146,"slug":147},30,"research-report",{"id":149,"doc_module":4,"doc_module_name":25,"category_name":150,"show_sort_weight":151,"slug":152},9,"Religion & Spirituality",20,"religion-spirituality",{"id":151,"doc_module":4,"doc_module_name":25,"category_name":154,"show_sort_weight":151,"slug":155},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":157,"show_sort_weight":55,"slug":158},"Lifestyle","lifestyle",{"id":92,"doc_module":4,"doc_module_name":25,"category_name":160,"show_sort_weight":131,"slug":161},"General","general"]